Entera Bio Ltd. Ordinary Shares ENTX

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

• GlobeNewswire Inc. 31 jul

  Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

  Entera Bio Ltd. (NASDAQ: ENTX), a clinical-stage biopharmaceutical company developing oral peptide therapies, announced that CEO Miranda Toledano will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The company is advancing its lead candidate EB613 (oral PTH(1-34)) for osteoporosis treatment, which met primary and secondary endpoints in a Phase 2 study, with positive FDA feedback received on planned Phase 3 registrational studies.

  

• GlobeNewswire Inc. 23 jun

  Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market

  Entera Bio received positive FDA feedback on its Phase 3 protocol for EB613, an oral osteoporosis tablet based on teriparatide. The FDA accepted the company's proposed single-study registrational strategy with approximately 750 postmenopausal women, using total hip bone mineral density at 12 months as the primary endpoint. Phase 3 is expected to initiate in late 2026 with topline results anticipated in H2 2028. The approval could represent the first oral anabolic osteoporosis treatment, addressing a market where injectable therapies have limited adoption despite high efficacy.